Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price Target & Predictions
JAZZ Stock Forecast
Jazz Pharmaceuticals stock forecast is as follows: an average price target of $182.75 (represents a 50.11% upside from JAZZ’s last price of $121.74) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
JAZZ Price Target
The average price target for Jazz Pharmaceuticals (JAZZ) is $182.75 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $230.00 to $160.00. This represents a potential 50.11% upside from JAZZ's last price of $121.74.
JAZZ Analyst Ratings
According to 7 Wall Street analysts, Jazz Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for JAZZ stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Jazz Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | Akash Tewar | Jefferies | $160.00 | $125.10 | 27.90% | 31.43% |
| Nov 18, 2024 | Joel Beatty | Robert W. Baird | $162.00 | $122.00 | 32.79% | 33.07% |
| Oct 23, 2024 | Daniel Busb | RBC Capital | $179.00 | $113.10 | 58.27% | 47.03% |
| Sep 11, 2024 | Annabel Samimy | Stifel Nicolaus | $230.00 | $105.22 | 118.59% | 88.93% |
| Jun 05, 2024 | Andrea Tan | Goldman Sachs | $169.00 | $104.48 | 61.75% | 38.82% |
| May 02, 2024 | Daniel Busb | RBC Capital | $176.00 | $110.31 | 59.55% | 44.57% |
| Mar 20, 2024 | David Amsellem | Piper Sandler | $188.00 | $124.79 | 50.65% | 54.43% |
| Dec 09, 2022 | Goldman Sachs | $190.00 | $150.07 | 26.61% | 56.07% | |
| Nov 10, 2022 | Goldman Sachs | $192.00 | $149.90 | 28.09% | 57.71% | |
| Nov 10, 2022 | RBC Capital | $207.00 | $149.90 | 38.09% | 70.03% | |
| Jun 20, 2022 | David Amsellem | Piper Sandler | $193.00 | $142.91 | 35.05% | 58.53% |
| Jun 13, 2022 | Ashwani Verma | UBS | $194.00 | $141.59 | 37.02% | 59.36% |
| Mar 03, 2022 | Ami Fadia | Needham | $215.00 | $152.90 | 40.61% | 76.61% |
| Jan 20, 2022 | Greg Fraser | Truist Financial | $200.00 | $139.13 | 43.75% | 64.28% |
| Jan 14, 2022 | Annabel Samimy | Stifel Nicolaus | $210.00 | $144.30 | 45.53% | 72.50% |
| Jan 03, 2022 | Aaron Gal | Bernstein | $175.00 | $131.01 | 33.58% | 43.75% |
| Nov 10, 2021 | Jason Gerberry | Bank of America Securities | $193.00 | $136.32 | 41.58% | 58.53% |
| Oct 06, 2021 | Brandon Folkes | Cantor Fitzgerald | $210.00 | $136.91 | 53.39% | 72.50% |
| Oct 05, 2021 | Navann Ty | Citigroup | $200.00 | $128.08 | 56.15% | 64.28% |
| Jun 22, 2021 | Balaji Prasad | Barclays | $250.00 | $177.30 | 41.00% | 105.36% |
| Jun 18, 2021 | Esther Rajavelu | UBS | $234.00 | $177.28 | 31.99% | 92.21% |
| May 10, 2021 | Ken Cacciatore | Cowen & Co. | $200.00 | $176.10 | 13.57% | 64.28% |
The latest Jazz Pharmaceuticals stock forecast, released on Nov 21, 2024 by Akash Tewar from Jefferies, set a price target of $160.00, which represents a 27.90% increase from the stock price at the time of the forecast ($125.10), and a 31.43% increase from JAZZ last price ($121.74).
Jazz Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 7 |
| Avg Price Target | $161.00 | $167.00 | $180.57 |
| Last Closing Price | $121.74 | $121.74 | $121.74 |
| Upside/Downside | 32.25% | 37.18% | 48.32% |
In the current month, the average price target of Jazz Pharmaceuticals stock is $161.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 32.25% increase as opposed to Jazz Pharmaceuticals's last price of $121.74. This month's average price target is down -3.59% compared to last quarter, and down -10.84% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 21, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 23, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Oct 04, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 09, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 09, 2024 | UBS | Underperform | Underperform | Hold |
| Aug 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 01, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jul 02, 2024 | UBS | Buy | Buy | Hold |
| Jun 06, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 05, 2024 | Needham | Underperform | Underperform | Hold |
| Jun 05, 2024 | Piper Sandler | Buy | Buy | Hold |
| May 29, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 02, 2024 | UBS | Buy | Buy | Hold |
| May 02, 2024 | RBC Capital | Underperform | Underperform | Hold |
| May 02, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Mar 20, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Mar 20, 2024 | UBS | Buy | Buy | Hold |
| Feb 29, 2024 | Barclays | Underperform | Underperform | Hold |
| Feb 29, 2024 | Needham | Buy | Buy | Hold |
| Jan 29, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Jan 29, 2024 | UBS | Buy | Buy | Hold |
| Aug 14, 2023 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| May 30, 2023 | Needham | Buy | Buy | Hold |
| Dec 08, 2022 | Goldman Sachs | Buy | Upgrade | |
| Jun 20, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 13, 2022 | UBS | Buy | Initialise | |
| Apr 26, 2022 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Mar 03, 2022 | Needham | Buy | Buy | Hold |
Jazz Pharmaceuticals's last stock rating was published by Jefferies on Nov 21, 2024. The company gave JAZZ a "Buy" rating, the same as its previous rate.
Jazz Pharmaceuticals Financial Forecast
Jazz Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $957.32M | $892.81M | $972.12M | $940.65M | $932.88M | $813.72M | $896.73M | $838.12M | $751.81M | $607.58M | $665.52M | $600.89M | $562.44M | $534.73M | $581.74M | $537.70M | $534.13M | $508.19M | $444.61M | $376.05M |
| Avg Forecast | $1.15B | $1.10B | $1.06B | $988.73M | $1.06B | $1.04B | $1.01B | $953.97M | $1.01B | $968.41M | $941.99M | $897.39M | $975.48M | $939.98M | $902.49M | $852.45M | $864.30M | $832.01M | $731.89M | $609.32M | $638.84M | $577.62M | $503.21M | $544.56M | $560.55M | $523.89M | $508.25M | $465.93M | $414.76M | $380.98M |
| High Forecast | $1.20B | $1.14B | $1.11B | $1.04B | $1.08B | $1.04B | $1.01B | $955.74M | $1.07B | $968.70M | $980.37M | $933.95M | $1.02B | $939.98M | $902.49M | $852.45M | $864.30M | $832.01M | $731.89M | $609.32M | $638.84M | $577.62M | $503.21M | $544.56M | $560.55M | $523.89M | $508.25M | $465.93M | $497.71M | $457.18M |
| Low Forecast | $1.09B | $1.04B | $1.01B | $936.96M | $1.03B | $1.04B | $1.01B | $952.19M | $957.26M | $968.12M | $891.68M | $849.46M | $923.38M | $939.98M | $902.49M | $852.45M | $864.30M | $832.01M | $731.89M | $609.32M | $638.84M | $577.62M | $503.21M | $544.56M | $560.55M | $523.89M | $508.25M | $465.93M | $331.81M | $304.79M |
| # Analysts | 4 | 4 | 4 | 6 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.02% | 0.99% | 1.00% | 1.00% | 1.03% | 0.95% | 1.04% | 1.01% | 1.03% | 1.00% | 1.04% | 1.04% | 1.12% | 0.98% | 1.04% | 1.03% | 1.05% | 1.09% | 1.07% | 0.99% |
Jazz Pharmaceuticals's average Quarter revenue forecast for Sep 23 based on 9 analysts is $968.41M, with a low forecast of $968.12M, and a high forecast of $968.70M. JAZZ's average Quarter revenue forecast represents a 1.16% increase compared to the company's last Quarter revenue of $957.32M (Jun 23).
Jazz Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 6 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $157.64M | $276.84M | $249.00M | $307.24M | $310.90M | $267.26M | $205.40M | $190.06M | $82.04M | $240.20M | $243.43M | $266.44M | $263.48M | $-123.25M | $235.66M | $197.89M | $266.41M | $192.66M | $142.47M | $163.31M |
| Avg Forecast | $360.33M | $342.87M | $332.05M | $308.99M | $330.29M | $323.94M | $315.63M | $314.37M | $314.59M | $302.64M | $294.38M | $285.79M | $322.60M | $331.28M | $318.07M | $259.81M | $304.61M | $293.23M | $257.94M | $226.60M | $225.15M | $203.57M | $177.35M | $-163.72M | $197.55M | $184.63M | $179.12M | $161.57M | $132.19M | $165.43M |
| High Forecast | $375.01M | $356.84M | $345.58M | $325.02M | $336.52M | $324.22M | $316.74M | $377.25M | $333.28M | $302.73M | $306.38M | $342.95M | $387.12M | $331.28M | $318.07M | $311.78M | $304.61M | $293.23M | $257.94M | $271.92M | $225.15M | $203.57M | $177.35M | $-130.98M | $197.55M | $184.63M | $179.12M | $193.88M | $158.62M | $198.52M |
| Low Forecast | $341.08M | $324.56M | $314.32M | $292.81M | $320.94M | $323.65M | $314.51M | $251.50M | $299.16M | $302.55M | $278.66M | $228.64M | $258.08M | $331.28M | $318.07M | $207.85M | $304.61M | $293.23M | $257.94M | $181.28M | $225.15M | $203.57M | $177.35M | $-196.46M | $197.55M | $184.63M | $179.12M | $129.25M | $105.75M | $132.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.54% | 0.97% | 0.77% | 0.93% | 0.98% | 1.03% | 0.67% | 0.65% | 0.32% | 1.06% | 1.08% | 1.31% | 1.49% | 0.75% | 1.19% | 1.07% | 1.49% | 1.19% | 1.08% | 0.99% |
9 analysts predict JAZZ's average Quarter EBITDA for Sep 23 to be $302.64M, with a high of $302.73M and a low of $302.55M. This is 91.99% upper than Jazz Pharmaceuticals's previous annual EBITDA (Jun 23) of $157.64M.
Jazz Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 6 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $104.44M | $69.42M | $-239.95M | $-17.10M | $34.66M | $5.79M | $-32.36M | $-52.83M | $-363.32M | $121.83M | $133.41M | $148.23M | $114.80M | $-157.83M | $73.99M | $102.28M | $261.90M | $85.20M | $45.99M | $86.51M |
| Avg Forecast | $373.08M | $361.74M | $353.85M | $288.71M | $365.54M | $347.35M | $310.95M | $2.05M | $327.54M | $311.60M | $280.83M | $1.86M | $176.81M | $324.50M | $290.91M | $1.69M | $252.80M | $231.05M | $244.81M | $114.94M | $295.04M | $283.78M | $216.71M | $-209.66M | $286.90M | $250.30M | $249.22M | $71.45M | $42.69M | $87.61M |
| High Forecast | $392.84M | $380.90M | $372.59M | $363.18M | $393.56M | $348.51M | $315.69M | $2.46M | $349.96M | $312.72M | $295.71M | $2.24M | $212.17M | $324.50M | $290.91M | $2.03M | $252.80M | $231.05M | $244.81M | $137.92M | $295.04M | $283.78M | $216.71M | $-167.73M | $286.90M | $250.30M | $249.22M | $85.74M | $51.23M | $105.13M |
| Low Forecast | $347.18M | $336.63M | $329.29M | $250.08M | $306.95M | $346.19M | $306.21M | $1.64M | $305.12M | $310.48M | $261.34M | $1.49M | $141.44M | $324.50M | $290.91M | $1.36M | $252.80M | $231.05M | $244.81M | $91.95M | $295.04M | $283.78M | $216.71M | $-251.59M | $286.90M | $250.30M | $249.22M | $57.16M | $34.15M | $70.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.37% | 37.25% | -1.36% | -0.05% | 0.12% | 3.42% | -0.13% | -0.23% | -1.48% | 1.06% | 0.45% | 0.52% | 0.53% | 0.75% | 0.26% | 0.41% | 1.05% | 1.19% | 1.08% | 0.99% |
Jazz Pharmaceuticals's average Quarter net income forecast for Sep 23 is $311.60M, with a range of $310.48M to $312.72M. JAZZ's average Quarter net income forecast represents a 198.36% increase compared to the company's last Quarter net income of $104.44M (Jun 23).
Jazz Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 6 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $340.84M | $297.92M | $383.20M | $358.48M | $366.47M | $308.81M | $398.46M | $363.68M | $429.03M | $260.51M | $247.17M | $207.25M | $191.41M | $208.40M | $214.28M | $178.71M | $176.01M | $167.95M | $207.21M | $144.25M |
| Avg Forecast | $440.21M | $418.88M | $405.67M | $377.49M | $403.52M | $395.75M | $385.60M | $384.37M | $384.33M | $369.74M | $359.65M | $349.43M | $327.56M | $355.85M | $341.66M | $317.66M | $327.20M | $314.98M | $277.08M | $245.76M | $241.85M | $218.68M | $190.51M | $276.83M | $212.21M | $198.33M | $192.41M | $140.84M | $192.31M | $146.10M |
| High Forecast | $458.15M | $435.95M | $422.20M | $397.08M | $411.13M | $396.10M | $386.96M | $461.24M | $407.16M | $369.85M | $374.30M | $419.31M | $393.07M | $355.85M | $341.66M | $381.19M | $327.20M | $314.98M | $277.08M | $294.91M | $241.85M | $218.68M | $190.51M | $332.20M | $212.21M | $198.33M | $192.41M | $169.01M | $230.77M | $175.33M |
| Low Forecast | $416.70M | $396.51M | $384.01M | $357.73M | $392.10M | $395.41M | $384.24M | $307.49M | $365.48M | $369.62M | $340.44M | $279.54M | $262.05M | $355.85M | $341.66M | $254.13M | $327.20M | $314.98M | $277.08M | $196.61M | $241.85M | $218.68M | $190.51M | $221.46M | $212.21M | $198.33M | $192.41M | $112.67M | $153.84M | $116.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.95% | 0.85% | 1.17% | 1.01% | 1.07% | 0.97% | 1.22% | 1.15% | 1.55% | 1.06% | 1.02% | 0.95% | 1.00% | 0.75% | 1.01% | 0.90% | 0.91% | 1.19% | 1.08% | 0.99% |
Jazz Pharmaceuticals's average Quarter SG&A projection for Sep 23 is $369.74M, based on 9 Wall Street analysts, with a range of $369.62M to $369.85M. The forecast indicates a 8.48% rise compared to JAZZ last annual SG&A of $340.84M (Jun 23).
Jazz Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 6 | 13 | 7 | 6 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | $1.63 | $1.09 | $-3.81 | $-0.27 | $0.56 | $0.09 | $-0.53 | $-0.86 | $-6.11 | $2.16 | $2.39 | $2.67 | $2.07 | $-2.82 | $1.31 | $1.80 | $4.62 | $1.49 | $0.77 | $1.44 |
| Avg Forecast | $5.91 | $5.73 | $5.60 | $4.57 | $5.79 | $5.50 | $4.92 | $4.18 | $5.18 | $4.93 | $4.45 | $4.24 | $0.88 | $4.66 | $4.18 | $3.84 | $3.63 | $3.32 | $3.52 | $3.73 | $4.24 | $4.08 | $3.11 | $0.64 | $4.12 | $3.60 | $3.58 | $3.16 | $2.58 | $2.37 |
| High Forecast | $6.22 | $6.03 | $5.90 | $5.75 | $6.23 | $5.52 | $5.00 | $4.19 | $5.54 | $4.95 | $4.68 | $4.46 | $0.93 | $4.66 | $4.18 | $3.84 | $3.63 | $3.32 | $3.52 | $3.73 | $4.24 | $4.08 | $3.11 | $0.64 | $4.12 | $3.60 | $3.58 | $3.16 | $3.10 | $2.84 |
| Low Forecast | $5.50 | $5.33 | $5.21 | $3.96 | $4.86 | $5.48 | $4.85 | $4.17 | $4.83 | $4.91 | $4.14 | $3.95 | $0.82 | $4.66 | $4.18 | $3.84 | $3.63 | $3.32 | $3.52 | $3.73 | $4.24 | $4.08 | $3.11 | $0.64 | $4.12 | $3.60 | $3.58 | $3.16 | $2.06 | $1.90 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.37% | 0.26% | -4.32% | -0.06% | 0.13% | 0.02% | -0.15% | -0.26% | -1.74% | 0.58% | 0.56% | 0.66% | 0.67% | -4.42% | 0.32% | 0.50% | 1.29% | 0.47% | 0.30% | 0.61% |
According to 9 Wall Street analysts, Jazz Pharmaceuticals's projected average Quarter EPS for Sep 23 is $4.93, with a low estimate of $4.91 and a high estimate of $4.95. This represents a 202.60% increase compared to JAZZ previous annual EPS of $1.63 (Jun 23).
Jazz Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| LEGN | Legend Biotech | $34.68 | $89.60 | 158.36% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| RARE | Ultragenyx Pharmaceutical | $44.95 | $90.00 | 100.22% | Buy |
| LQDA | Liquidia | $11.31 | $22.33 | 97.44% | Buy |
| PCVX | Vaxcyte | $89.86 | $148.80 | 65.59% | Buy |
| DNLI | Denali Therapeutics | $23.22 | $35.00 | 50.73% | Buy |
| ASND | Ascendis Pharma | $140.30 | $211.14 | 50.49% | Buy |
| JAZZ | Jazz Pharmaceuticals | $122.49 | $182.75 | 49.20% | Buy |
| PTGX | Protagonist Therapeutics | $40.69 | $57.33 | 40.89% | Buy |
| BMRN | BioMarin Pharmaceutical | $67.19 | $94.43 | 40.54% | Buy |
| INCY | Incyte | $69.40 | $90.11 | 29.84% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |
| ALNY | Alnylam Pharmaceuticals | $246.58 | $310.60 | 25.96% | Buy |
| UTHR | United Therapeutics | $379.69 | $440.40 | 15.99% | Buy |
| TECH | Bio-Techne | $75.27 | $82.33 | 9.38% | Buy |
| VRDN | Viridian Therapeutics | $20.82 | $22.75 | 9.27% | Buy |
| HALO | Halozyme Therapeutics | $48.60 | $52.00 | 7.00% | Buy |
| EXEL | Exelixis | $34.69 | $30.89 | -10.95% | Buy |
| ARGX | argenx SE | $638.33 | $558.78 | -12.46% | Buy |